Programmed release tablets containing naproxen
Patent 5480650 Issued on January 2, 1996. Estimated Expiration Date: 
September 1, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 1, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesGalenic formulations with programmed release containing naproxen Dosage form providing immediate therapy followed by prolonged therapy Dosage form for time-varying patterns of drug delivery Patent #: 5232705 InventorsAssigneeApplicationNo. 115897 filed on 09/01/1993US Classes:424/464, Tablets, lozenges, or pills424/468, Sustained or differential release type424/470, Where particles are granulated424/489Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)ExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmInternational ClassA61K 009/20Foreign Application Priority Data1992-09-11 ITAbstractProgrammed release tablets, to be administered by oral route, containing from 500 to 1,200 mg of naproxen, made by mixtures of an immediate release granulate dry compacted containing from 5% to 28% of naproxen, of a controlled release granulate dry compacted containing from 72% to 95% of naproxen and of a disintegrating agent. A portion of naproxen is released in a short time, so that the drug can quickly develop its therapeutic action reaching the necessary hematic levels, while the remaining portion is released in a longer interval of time, so as to allow the therapeutic coverage until the subsequent administration. The therapeutic coverage is effective for a period of 24 hours; thus the tablets object of the present invention are suitable for a once a day administration. | |
